AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25648342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and daily tadalafil (5 mg) for 30 weeks
Number of subjects: 60
Study 25648342 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and on-demand tadalafil (10-20 mg) for 30 weeks
Number of subjects: 60
Study 25648342 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same testosterone treatment but with on-demand tadalafil (10-20 mg)
Number of subjects: 60
Study 25648342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (daily tadalafil 5 mg)
Number of subjects: 60
Study 22882805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 269
Study 22882805 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 269
Study 21198671 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated vaccines
Number of subjects: 0
Study 21198671 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccines
Number of subjects: 0
Study 21198671 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccines with oil-in-water emulsion adjuvants (e.g., MF59)
Number of subjects: 0
Study 21198671 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted inactivated vaccines
Number of subjects: 0
Study 18945572 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia CD-ROM
Number of subjects: 101
Study 18945572 — intervention group
Group type: COMPARATOR
Intervention: Standard written information
Number of subjects: 101
Study 16513877 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 61
Study 16513877 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 61
Study 12937039 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine polymerase chain reaction (PCR)
Number of subjects: 2000
Study 12937039 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine culture
Number of subjects: 2000
Study 12937039 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CMV IgM antibodies
Number of subjects: 2000
Study 12937039 — intervention group
Group type: EXPERIMENTAL
Intervention: Full clinical evaluation
Number of subjects: 2000
Study 11106042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg)
Number of subjects: 167
Study 9345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular lingual arch
Number of subjects: 30
Study 9345158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 8243687 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate + depot‐MPA
Number of subjects: 96
Study 8243687 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐nortestosterone ester + depot‐MPA
Number of subjects: 96
Study 8243687 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 96
Study 8243687 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐nortestosterone group
Number of subjects: 96
Study 3545882 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostim 2 mg/day
Number of subjects: 198
Study 3545882 — intervention group
Group type: COMPARATOR
Intervention: Biostim 8 mg/day
Number of subjects: 198
Study 3545882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 31503274 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25mg weekly)
Number of subjects: 216
Study 31503274 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (3g daily)
Number of subjects: 216
Study 29710284 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS guidelines score of 5 to 6 (n=91; 9%)
Number of subjects: 992
Study 29710284 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS guidelines score of 6 to 8 (n=162; 16%)
Number of subjects: 992
Study 29710284 — intervention group
Group type: COMPARATOR
Intervention: ACS guidelines score of 0 to 1 (n=262; 26%)
Number of subjects: 992
Study 29710284 — intervention group
Group type: COMPARATOR
Intervention: ACS guidelines score of 0 to 2 (n=187; 91%)
Number of subjects: 992
Study 28053650 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Difference Pattern (LDP) and combined classifier
Number of subjects: 0
Study 24383914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine (Typherix(®))
Number of subjects: 50
Study 24383914 — intervention group
Group type: COMPARATOR
Intervention: Ty21a vaccine (Vivotif(®))
Number of subjects: 50
Study 22517480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients informed of monitoring (10 patients)
Number of subjects: 21
Study 22517480 — intervention group
Group type: COMPARATOR
Intervention: Patients uninformed of monitoring (11 patients)
Number of subjects: 21
Study 20143119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 44
Study 20143119 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 44
Study 16638070 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied criteria for detecting individuals at risk of psychosis
Number of subjects: 0
Study 16638070 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15849398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (group A)
Number of subjects: 87
Study 15849398 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (group B)
Number of subjects: 87
Study 11296170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with two cycles of two‐min ischemia followed by 3‐min reperfusion before cross‐clamping
Number of subjects: 40
Study 11296170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 40
Study 9257789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of budesonide
Number of subjects: 10
Study 9257789 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of budesonide
Number of subjects: 10
Study 9257789 — intervention group
Group type: EXPERIMENTAL
Intervention: D5159 (8 mg)
Number of subjects: 10
Study 9257789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8421248 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg/kg
Number of subjects: 24
Study 8421248 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3.0 mg/kg
Number of subjects: 24
Study 8421248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0 mg/kg caffeine)
Number of subjects: 24
Study 8421248 — intervention group
Group type: EXPERIMENTAL
Intervention: Introverts
Number of subjects: 24
Study 8421248 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraverts
Number of subjects: 24
Study 8421248 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 24
Study 3555276 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of diclofenac
Number of subjects: 60
Study 3555276 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 31327292 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly group-exercises and physical activity counselling
Number of subjects: 80
Study 31327292 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 80
Study 30483937 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (ten sessions with three types of wavelengths)
Number of subjects: 17
Study 30483937 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side of the scars)
Number of subjects: 17
Study 29421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban-based strategy (60 mg or 30 mg once daily) plus P2Y12 antagonist (clopidogrel, 75 mg once daily) for 12 months
Number of subjects: 1500
Study 29421002 — intervention group
Group type: COMPARATOR
Intervention: VKA-based strategy (VKA plus P2Y12 antagonist and acetylsalicylic acid 100 mg once daily) for 30 days to 12 months
Number of subjects: 1500
Study 29421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban-based strategy
Number of subjects: 1500
Study 29421002 — intervention group
Group type: COMPARATOR
Intervention: VKA-based strategy
Number of subjects: 1500
Study 27480131 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐1X 750 mg and sulindac 150 mg
Number of subjects: 138
Study 27480131 — intervention group
Group type: COMPARATOR
Intervention: CPP‐1X placebo and sulindac 150 mg
Number of subjects: 138
Study 27480131 — intervention group
Group type: COMPARATOR
Intervention: CPP‐1X 750 mg and sulindac placebo
Number of subjects: 138
Study 24793258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-related behaviour (suntan, sunbathing, sunburn, sunscreen use, sunbed use)
Number of subjects: 2173
Study 24793258 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer awareness
Number of subjects: 2173
Study 24793258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanning attitudes
Number of subjects: 2173
Study 24793258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in sun-related behaviours
Number of subjects: 2173
Study 21935581 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial epicardial cryoablation and LAA closure (ABL group, n=30)
Number of subjects: 65
Study 21935581 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group, n=35)
Number of subjects: 65
Study 21935581 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial epicardial cryoablation and LAA closure (ABL group)
Number of subjects: 65
Study 21935581 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group)
Number of subjects: 65
Study 20620634 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom criteria alone
Number of subjects: 202
Study 20620634 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom criteria plus nasal endoscopy
Number of subjects: 202
Study 18418791 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 182
Study 18418791 — intervention group
Group type: COMPARATOR
Intervention: Equal contact control
Number of subjects: 182
Study 18418791 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 182
Study 17198904 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 Peptide (3.8 g daily for 4 weeks)
Number of subjects: 48
Study 17198904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12603176 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice daily for 5.5 days
Number of subjects: 9
Study 12603176 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 6 days
Number of subjects: 9
Study 12603176 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice daily and Simvastatin 40 mg once daily
Number of subjects: 9
Study 10649881 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-rotational powered toothbrush
Number of subjects: 2966
Study 10649881 — intervention group
Group type: COMPARATOR
Intervention: Manual methods
Number of subjects: 2966
Study 9096658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) >4,000 mg/m2
Number of subjects: 604
Study 9096658 — intervention group
Group type: COMPARATOR
Intervention: None (AGDS cohort)
Number of subjects: 604
Study 8117631 — intervention group
Group type: EXPERIMENTAL
Intervention: SPGBlidocaine
Number of subjects: 16
Study 8117631 — intervention group
Group type: COMPARATOR
Intervention: SPGBsaline
Number of subjects: 16
Study 3516764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-enriched meals
Number of subjects: 7
Study 3516764 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-enriched meals
Number of subjects: 7
Study 3516764 — intervention group
Group type: COMPARATOR
Intervention: Bread-enriched meals
Number of subjects: 7
Study 29185087 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive devices for daily life activities
Number of subjects: 39
Study 29185087 — intervention group
Group type: COMPARATOR
Intervention: Guideline leaflet with information on joint protection and disease features
Number of subjects: 39
Study 27548766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid daily, n=7545)
Number of subjects: 15104
Study 27548766 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg daily, n=7559)
Number of subjects: 15104
Study 27548766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid among participants with CKD
Number of subjects: 15104
Study 27548766 — intervention group
Group type: COMPARATOR
Intervention: Enalapril among participants with CKD
Number of subjects: 15104
Study 27548766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid among those without CKD
Number of subjects: 15104
Study 25335675 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (20 g per day)
Number of subjects: 82
Study 25335675 — intervention group
Group type: COMPARATOR
Intervention: Control group (enteral formula without arginine)
Number of subjects: 82
Study 23736156 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education pulmonary rehabilitation programme
Number of subjects: 350
Study 23736156 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 20492851 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) at 10 mg for 1 week and then 20 mg for 1 week
Number of subjects: 30
Study 20492851 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system (PTS)
Number of subjects: 30
Study 19057626 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Number of subjects: 72
Study 19057626 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 72
Study 16643445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (including autologous stem cell transplantation) for patients <60 years
Number of subjects: 452
Study 16643445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (including autologous stem cell transplantation) for patients aged 60-64 years
Number of subjects: 452
Study 16643445 — intervention group
Group type: COMPARATOR
Intervention: Historic control group (conventionally treated patients) for patients <60 years
Number of subjects: 452
Study 16643445 — intervention group
Group type: COMPARATOR
Intervention: Historic control group (conventionally treated patients) for patients aged 60-64 years
Number of subjects: 452
Study 12794815 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 79
Study 10831180 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 47
Study 10831180 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 47
Study 8772604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU daily for 5 days/week) plus 1000 mg calcium daily
Number of subjects: 46
Study 8772604 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone (1000 mg daily)
Number of subjects: 46
Study 8772604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 1630044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular beta-agonist inhalation
Number of subjects: 20
Study 1630044 — intervention group
Group type: COMPARATOR
Intervention: As required beta-agonist inhalation
Number of subjects: 20
Study 6481113 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic gastritis in GER patients
Number of subjects: 23
Study 6481113 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe gastritis (grades 2 or 3) in GER patients
Number of subjects: 23
Study 6481113 — intervention group
Group type: COMPARATOR
Intervention: Grades 0 or 1 gastritis in GER patients
Number of subjects: 23
Study 6481113 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 23
Study 31592623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/kg of CHO beverage
Number of subjects: 10
Study 31592623 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric PLA
Number of subjects: 10
Study 29076967 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised mock codes with debriefing
Number of subjects: 0
Study 29076967 — intervention group
Group type: COMPARATOR
Intervention: Just-in-time training with a peer
Number of subjects: 0
Study 25788018 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme on harmful effects of salt and how to reduce salt intake delivered to children for one school term (about 3.5 months).
Number of subjects: 832
Study 25788018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 832
Study 23142014 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic sliding intervention
Number of subjects: 28
Study 23142014 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 28
Study 21568985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-plexus blocks
Number of subjects: 170
Study 21568985 — intervention group
Group type: COMPARATOR
Intervention: Peri-plexus blocks
Number of subjects: 170
Study 19305279 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP group (mean cuff pressure 151 mm Hg)
Number of subjects: 21
Study 19305279 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean cuff pressure 300 mm Hg)
Number of subjects: 21
Study 19305279 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical control data (250 mm Hg)
Number of subjects: 21
Study 16766544 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-containing soy-based nutritional supplements for 8 weeks
Number of subjects: 32
Study 16766544 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone-free milk protein for 8 weeks (Control group)
Number of subjects: 32
Study 15616415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 1181
Study 15616415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1181
Study 11422000 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (7 mg loading dose on day 1, followed by 1 mg daily on days 2-11)
Number of subjects: 16
Study 11422000 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 16
Study 11422000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9289406 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome patients
Number of subjects: 48
Study 9289406 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 9289406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 8281831 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy without immobilisation
Number of subjects: 41
Study 8281831 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilisation for six weeks
Number of subjects: 41
Study 3573541 — intervention group
Group type: EXPERIMENTAL
Intervention: L-triiodothyronine (T3) treatment
Number of subjects: 14
Study 3573541 — intervention group
Group type: COMPARATOR
Intervention: Sodium ipodate treatment
Number of subjects: 14
Study 29979940 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT) in addition to regular chest physiotherapy
Number of subjects: 40
Study 29979940 — intervention group
Group type: COMPARATOR
Intervention: Regular chest physiotherapy (Control Group)
Number of subjects: 40
Study 30939911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low thermal damage device
Number of subjects: 75
Study 30939911 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 75
Study 28724041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb (30.0 g/d) for 7 days
Number of subjects: 80
Study 28724041 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for 7 days
Number of subjects: 80
Study 25542311 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE‐PC + 21 Gy involved field radiation therapy (IFRT)
Number of subjects: 1712
Study 25542311 — intervention group
Group type: COMPARATOR
Intervention: ABVE‐PC
Number of subjects: 1712
Study 25542311 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE‐PC + 21 Gy IFRT
Number of subjects: 1712
Study 23680435 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (dose range around 10-15 mg/d)
Number of subjects: 21
Study 23680435 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 21542939 — intervention group
Group type: EXPERIMENTAL
Intervention: Training township hospital midwives and instructing them in how to provide systematic maternal care
Number of subjects: 0
Study 21542939 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing women in the community of the importance of prenatal care
Number of subjects: 0
Study 21542939 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing basic medical instruments to the hospitals
Number of subjects: 0
Study 21542939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 19931828 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Services (TSS)
Number of subjects: 179
Study 19931828 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (UC+)
Number of subjects: 179
Study 17004666 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed cotton blankets
Number of subjects: 0
Study 17004666 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled warming gowns
Number of subjects: 0
Study 15080852 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled on-demand treatment with esomeprazole, 20 mg daily
Number of subjects: 1357
Study 15080852 — intervention group
Group type: COMPARATOR
Intervention: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 2 weeks
Number of subjects: 1357
Study 15080852 — intervention group
Group type: COMPARATOR
Intervention: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 4 weeks
Number of subjects: 1357
Study 12160097 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers
Number of subjects: 187
Study 12160097 — intervention group
Group type: COMPARATOR
Intervention: Drinkers
Number of subjects: 187